GH Research (GHRS) Income from Discontinued Operations (2020 - 2025)
GH Research's (GHRS) quarterly Income from Discontinued Operations came in at 141000.0 in Q4 2025, up 92.74% year-on-year from 73157.18 in Q4 2024, and down 123.81% quarter-over-quarter from 63000.0 in Q3 2025.
GH Research (GHRS) Income from Discontinued Operations (2020 - 2025) Analysis & Trends
GH Research's Income from Discontinued Operations history runs 6 years deep, the most recent figure standing at 141000.0 for Q4 2025.
- On a quarterly basis, Income from Discontinued Operations rose 92.74% year-over-year to 141000.0 in Q4 2025; TTM through Dec 2025 was 785000.0, a 138.22% increase from a year earlier, with the FY2025 full-year figure at 785000.0, up 138.22% from the prior year.
- Income from Discontinued Operations fell to 141000.0 in Q4 2025 per GHRS's latest filing, from 63000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 8647000.0 in Q4 2022 and bottomed at 7054000.0 in Q2 2022.
- The 5-year median for Income from Discontinued Operations is 324000.0 (2021), against an average of 598800.0.
- Across the five-year window, Income from Discontinued Operations plunged 19066.67% in 2021 and jumped 436.46% in 2022, its largest moves.
- Year by year, Income from Discontinued Operations stood at 2570000.0 in 2021, then soared by 436.46% to 8647000.0 in 2022, then sank by 68.9% to 2689000.0 in 2023, then slumped by 172.18% to 1941000.0 in 2024, then soared by 92.74% to 141000.0 in 2025.
- Per Business Quant, the three latest GHRS Income from Discontinued Operations figures stand at 141000.0 (Q4 2025), 63000.0 (Q3 2025), and 457000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | - |
| 10 | GH Research | 1.70 Bn | 1.46 Bn | - | -141,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -141,000.00 |
| Sep 30, 2025 | -63,000.00 |
| Jun 30, 2025 | 457,000.00 |
| Mar 31, 2025 | 532,000.00 |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | -446,000.00 |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -57,000.00 |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 8.65 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -7.05 Mn |
| Mar 31, 2022 | -2.26 Mn |
| Dec 31, 2021 | -2.57 Mn |
| Sep 30, 2021 | -2.85 Mn |
| Jun 30, 2021 | -486,000.00 |
| Mar 31, 2021 | -202,000.00 |